Mark L. Fuerst

A combination of cobimetinib and vemurafenib prolongs overall survival in melanoma patients with BRAF V600 mutations.

The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.

A combination of pembrolizumab and low-dose ipilimumab appears to be active and to have a better safety profile than a combination of nivolumab and full-dose ipilimumab in advanced melanoma patients.

Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.

Older men are more likely to be diagnosed with multiple primary melanomas and have worse cutaneous malignant melanoma–specific survival than men with a single primary melanoma.

Nivolumab alone or in combination with ipilimumab are promising treatment options for patients with mucosal melanoma, according to a new study.

The expression of immune markers and T-cell subsets can help predict outcomes of sentinel lymph node–positive melanoma patients, according to a new study.

The checkpoint inhibitors pembrolizumab and nivolumab not only prolong survival in advanced melanoma patients but also maintain health-related quality of life.

Advanced melanoma patients successfully treated with a combination of nivolumab and ipilimumab may endure severe side effects, but they do not suffer any clinically meaningful changes in health-related quality of life.

Five-year recurrence rates for women with ductal carcinoma in situ have been cut in half recently due to advances in mammography and more detailed pathology assessments.

Adjuvant radiation therapy after lumpectomy improves survival for elderly women with early-stage, triple-negative breast cancer, according to a study to be presented at the 2015 ASCO Breast Cancer Symposium.

Whole brain radiation therapy helps control tumor growth in patients with 1 to 3 small brain metastases, but it does not significantly extend patient survival.

A combination of lenvatinib plus everolimus improved survival and overall response compared with everolimus alone in metastatic renal cell carcinoma patients.

Early trial results found that the addition of olaratumab to doxorubicin dramatically improves survival in patients with advanced soft-tissue sarcoma.

Pembrolizumab demonstrates durable antitumor activity in patients with advanced urothelial cancer, with a higher response rate seen in patients with PD-L1 expression.

Advanced bladder cancer patients with poor prognosis appear to benefit from adding apatorsen 600 mg to first-line chemotherapy with gemcitabine/cisplatin.

The addition of bevacizumab to carboplatin/paclitaxel chemotherapy increases progression-free survival in advanced/recurrent endometrial cancer patients.

Treating advanced sarcoma with the chemotherapy agent eribulin improves overall survival compared with treatment with standard therapy with dacarbazine.

An analysis of more than 34,000 5-year survivors of childhood cancer treated over 3 decades finds that modern treatments have reduced long-term mortality rates.

Elective neck lymph node surgery for patients with early oral cancer reduces the risk of cancer recurrence and improves survival.

The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.